A phase IV, open-label study of the adhesion and dermal tolerability of EMSAM (selegiline transdermal system) in healthy adults subjects of two age groups (18-64 years, and 65 years and older)
Latest Information Update: 18 Jan 2010
At a glance
- Drugs Selegiline (Primary)
- Indications Alzheimer's disease; Depressive disorders; Parkinson's disease
- Focus Pharmacodynamics
- Sponsors Somerset Pharmaceuticals
- 04 Oct 2007 New trial record.